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ABSTRACT
Objectives To explore the bodily and relational
experience of taking antiretroviral therapy (ART) and the
subsequent effect on retention in HIV care in six sub-
Saharan African countries.
Methods In-depth interviews were conducted with 130
people living with HIV (PLHIV) who had initiated ART,
38 PLHIV who were lost to follow-up and 53 healthcare
workers (HCWs) in Kenya, Uganda, Tanzania, Malawi,
Zimbabwe and South Africa. PLHIV were purposely
selected to include a range of HIV treatment histories.
Deductive and inductive analysis was guided by aspects
of practice theory; retention in HIV care following ART
initiation was the practice of interest.
Results PLHIV who were engaged in HIV care took
ART every day, attended clinic appointments and ate as
well as possible. For PLHIV, biomedical markers acted as
reassurance for their positive treatment progression.
However, many described ART side effects ranging from
dizziness to conditions severe enough to prevent them
from leaving home or caring for themselves or others. In
all settings, the primary concern of HCW was ensuring
patients achieved viral suppression, with management of
side effects seen as a lower priority. Where PLHIV
tolerated side effects, they were deemed the lesser of
two evils compared with their pre-ART illnesses.
Participants who reported feeling well prior to starting
ART were often less able to tolerate side effects, and in
many cases these events triggered their disengagement
from HIV care.
Conclusions Retention in ART care is rarely an
outcome of rational decision-making, but the
consequence of bodily and relational experiences.
Initiatives to improve retention should consider how
bodily experiences of PLHIV relate to the rest of their
lives and how this can be respected and supported by
service providers to subsequently improve retention in
care.
BACKGROUND
Over the past decade, signiﬁcant achievements have
been made in bringing HIV care and treatment to
people living with HIV (PLHIV) in sub-Saharan
Africa, with approximately 13 million people on
antiretroviral therapy (ART) by the end of 2013.1
The transformational effects of ART are unques-
tionable, and the successful scale-up of national
HIV treatment programmes has enabled ambitious
goals to be established to eliminate AIDS by 2030.
This target can only be reached by achieving high
rates of testing, initiation of ART and viral suppres-
sion among PLHIV.1 2 However, systematic reviews
of retention in HIV care show suboptimal out-
comes in many African settings which can jeopard-
ise individual health outcomes and may undermine
public health initiatives to eliminate AIDS.3 4
ART side effects are a recognised factor that can
undermine treatment success.5 From a clinical and
public health perspective, the beneﬁts of viral sup-
pression that result from adherence to ART out-
weigh the risks associated with side effects or
uncontrolled viral replication. The extent to which
PLHIV perceive the trade-off in the same terms
and over time is less clear. Side effects have been
reported with the use of all ART drugs,6 with a
recent study in three African countries ﬁnding that
88% of participants described at least one side
effect during the preceding four weeks. Fatigue,
loss of energy, pain, numbness, headache and
depression were among the most frequently cited
side effects.7 The same study found that every add-
itional self-reported side effect increased the odds
of incomplete adherence by 10%.8 Few qualitative
studies have explored how these experiences affect
the daily lives of PLHIV and subsequently contrib-
ute to sustained or suspended retention on ART. In
this paper, we explore the bodily and relational
experience of taking ART and the subsequent effect
on retention in HIV care in six sub-Saharan African
countries.
Theoretical framework
Retention is an ongoing process corresponding to a
re-enactment of various practices over time in dif-
ferent social contexts. For PLHIV, these include
regularly attending HIV clinics, taking ART on a
daily basis, adhering to advice on ‘healthy living’
provided by healthcare workers (HCWs) and
adopting strategies to mediate the side effects of
treatment. Drawing on aspects of practice theory9
and the concept of ‘situated rationalities’,10 we
explore how the perceived and actual ability or
willingness of PLHIV to engage with the clinical
requirements of HIV treatment are inﬂuenced by
the experiences of their everyday activities, such as
work or social relationships, and how these aspects
of their lives relate to each. Practice theory unpicks
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the dynamic relationship between social structure and human
agency. Through a situational analysis we will be able to disen-
tangle how diverse social beings (in terms of motives and inten-
tions) form and are formed by the ‘rationalities’ of the world
which they live in.
METHODS
We draw on data from a large qualitative study investigating
health-seeking experiences of PLHIV in seven health and demo-
graphic surveillance sites (HDSS) in six African countries:
Uganda (Kyamulibwa, Rakai), Tanzania (Kisesa), South Africa
(uMkhanyakude), Kenya (Kisumu), Zimbabwe (Manicaland)
and Malawi (Karonga).11
Sampling frames were constructed for the larger study using
HDSS datasets and HIV clinic records to purposively sample
PLHIV with a range of care and treatment histories (n=264). A
purposive selection of HCWs with experience in providing HIV
diagnosis, care or treatment services (n=53) and family members
of PLHIV who had died (n=48). Additional methodological
details concerning the Bottlenecks study can be found in the
online supplementary material found within the editorial at
http://dx.doi.org/10.1136/sextrans-2017-053172.12 For the
purpose of this analysis, only PLHIV who had already initiated
ART (n=168) and HCWs (n=53) were included (table 1) (see
online supplementary ﬁle).
Face-to-face in-depth interviews (IDIs) lasted between 45 and
90 min and were conducted in private, either at homes or
clinics, by trained and qualiﬁed interviewers who had previous
experience of working in the HDSS. One-off IDIs with PLHIV
captured their life circumstances and their experiences of HIV
services and ART. One-off IDIs with HCW explored their
rapport with PLHIV, experiences of delivering HIV services and
their perceptions of the underlying drivers of retention on ART
among PLHIV. Repeat interviews were conducted where neces-
sary and ranged between 0 and 5 per site.
All IDIs were audio-recorded. In Kyamulibwa (Uganda), the
recordings were used to develop detailed accounts including
illustrative quotations, which were then translated into English.
Elsewhere, the recordings were transcribed and translated into
English. A broad coding framework was applied by each local
site coordinator to organise the data in relation to care and
treatment histories and other inﬂuences in the lives of PLHIV,
with summaries produced to document emerging themes. The
lead author reviewed these summaries and developed an analyt-
ical coding scheme based on elements of practice theory to
explore the PLHIV experiences of taking ART and how this
affected and was affected by the ‘rationalities’ of their daily
lives. An inductive coding approach was adopted to allow a
more nuanced exploration of emerging ideas (eg, experiences of
side effects) and thematic areas (eg, relational experiences
between previous experience of AIDS-deﬁning illnesses and
ability to cope with side effects).13 14
RESULTS
The sample included 130 PLHIV who had initiated ART, 38
PLHIV who were lost to follow-up (LTFU) and 53 HCWs (table 1).
Strategies and situations which helped to normalise taking
ART and retention in care
PLHIV who were retained on ARTreported taking their medica-
tion daily, attending clinic appointments and taking care to eat
as well as possible. Many took ARTafter their evening meal and
immediately prior to going to bed to mitigate frequently
reported feelings of dizziness or weakness. Those who took
their medication daily often described themselves as being well,
with many aware of their CD4 counts or at the very least the
utility of the measure, and some choosing to use this as a proxy
measure of their health status.
Food insecurity remained an inﬂuential factor affecting reten-
tion on ART, with many reporting challenges in securing
adequate food to maintain them while on drugs. Those who
were unable to eat sufﬁcient amounts reported that the dizziness
intensiﬁed, forcing them to take the drugs just prior to sleeping.
For many, this dizziness persisted even in the morning, with one
woman explaining how in the morning she could still ‘smell’ the
drugs if she had not been able to eat.
… when I haven’t eaten something in the morning around 09:00
after taking the medicine [ART], my whole body stinks due to
strength of the medicine … I need to eat food. (Female, PLHIV
—on ART >5 years, Malawi)
Experiences of side effects and engagement with HIV
services
Many PLHIV, particularly those routinely taking their ART,
reported favourably on their interactions with HCW and HIV
services. The nature of the interactions was particularly pertin-
ent when PLHIV were struggling to adjust to new treatments.
When an explanation for their symptoms was offered, and
support or encouragement given, it was often possible for
PLHIV to continue taking ART.
I took these pills and they made me feel dizzy. I could not walk
and would crawl to bed and I would see the house going in
circles but I came back here they encouraged me to continue
taking the pills.
(Female, PLHIV—on ART <5 years; Zimbabwe)
Acceptance, adjustment and management of life on ARTwere
particularly problematic when side effects developed later, after
already tolerating the adjustment period when ﬁrst starting ART.
Participants described debilitating side effects ranging from diz-
ziness and headaches through to pains and conditions severe
Table 1 The study participants shown by sampling category and
country
Country Demographic surveillance site HCWs
PLHIV
On ART* LTFU†
Uganda Rakai 6 15 6
Uganda Kyambuliwa 5 8 4
Kenya Kisumu 8 15 6
Tanzania Kisesa 7 20 4
Malawi Karonga 5 20 4
Zimbabwe Manicaland 4 35 8
South Africa uMkhanyakude 18 17 6
Total 53 130 38
The number of PLHIV sampled per setting varied due to the secondary sampling
objective for the wider study to include other variables (rather than just care and
treatment trajectories) that may influence the experiences of PLHIV in accessing HIV
services in their setting, such as their pregnancy status, area of residence or
livelihood, etc. The number of HCWs varied in accordance with the number and types
of clinics and HCWs in the HDSS providing HIV care.
*The PLHIV could have been taking ART for variable periods of time, countries had
varying cut-off points but generally captured recently initiated and then longer term
(over 5 years).
†PLHIV had not collected ART from their registered clinic for a country specific
predetermined period of time.
ART, antiretroviral therapy; HCWs, healthcare workers; HDSS, health and demographic
surveillance sites; LTFU, lost to follow-up; PLHIV, people living with HIV.
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enough to prevent them from leaving the house or caring for
themselves or their families. The consequences among PLHIV
varied, with some unable to attend clinic and sending treatment
partners to collect medication on their behalf, others reporting
their challenges to HCWs and some interrupting treatment.
I started feeling dizzy. I felt it for some time but I just kept it to
myself. I told nobody … I realised one tablet is the one which
made me have that feeling and I stopped taking it. (Male,
PLHIV–LTFU, Kenya)
The tension between the need for viral suppression and the
realities of dealing with side effects
HCWs in Kenya explained how, according to guidelines, they
are supposed to counsel all PLHIV who need to initiate treat-
ment three times prior to commencement:
Like when a client starts ART there are some side effects that he
might see, we need to treat the client of the side effects, things
like headache, drowsiness, loss of appetite, bad dreams, things
like that of which we have to inform or alert the client, if he
sees, these things will go away after 2–3 weeks, but the client is
not supposed to stop the drugs, he is supposed to continue with
the drugs, even things like rashes, they are so many, vomiting, so
according to the guideline, before we initiate clients, we have to
do ﬁrst adherence, we do the second adherence after 2 weeks,
then after one week we do the 3rd adherence, then we ﬁll the
pre HAART form for the client … we have to inform the client
of the side effects appropriately, yeah and also to encourage the
client not to stop the drugs, yeah. (HCW, Kenya)
However, in reality in all countries HCWs were reported to
‘ignore’ side effects or describe them as ‘normal’ while the
PLHIVs’ ‘bodies were adjusting to the drugs’ they were not used
to (HCW, Kenya). While some HCWs recognised that PLHIV
‘stop taking medicine because of reactions’ (HCW, Malawi), in
all settings, the HCWs’ primary focus was ensuring that PLHIV
achieved viral suppression. HCWs prioritised adherence moni-
toring which necessitated stringent pill counts, and where avail-
able, viral load testing either with or without health education.
The possibility of modifying treatment regimens to reduce side
effects was rarely mentioned by either HCWs or PLHIV. The
focus on viral suppression led to a lesser regard being placed on
the experiences and challenges of coping with side effects. One
PLHIV in Zimbabwe described that despite his efforts to articu-
late his daily struggles, the HCW was primarily focused on his
need to initiate ART; this divergence of priorities ultimately led
to him to disengage with care.
I had not taken them [ART] for many months because when I
started taking them my face, hands and legs started swelling.
Then they started peeling and my face becomes black … I went
to see a doctor at Hauna, the doctor did not tell me anything
that was satisfying, he just started by asking me what was happen-
ing to my face, I was burnt and dark. Then I told him it hap-
pened after I had taken the ARVs, my hands had peeled and my
feet … I visited the doctor twice and they would say I should
continue to take my medication. So I just wondered if I was safe
because of the continuous reaction, so I stayed at my home and I
stopped taking the medication. (Female, PLHIV–LTFU,
Zimbabwe)
The interviews with the HCWs did elucidate a level of sym-
pathy and understanding of the challenges that PLHIV faced.
However, their actions were hindered by the constraints of their
working environments including requirements to follow policies
dictating when ART should be started, what drugs were available
to them and how often to dispense.
The relation between the beneﬁts of ART and other aspects
of life and treatment
The practices we have described above relate to other aspects of
the PLHIV’s lives that inﬂuence their ‘practice of retention’,
thereby forming a mutually constituted duality or dichotomy
(a concept embedded within theories of practice),15 which
could either promote or inhibit engagement in care (ﬁgure 1).
Many PLHIV had experienced the transformational effects of
ART and described their return to a ‘normal’ life. This generally
referred to a restoration of activities associated with their lives
before they were affected by HIV. It also related to how they
perceived they should live in the context of social norms and
expectations, for example, the imperative to stay alive to care
for their dependents.
… I recall the way I was before I started ART and now, there’s a
big change so if I can just stop taking them now that means I will
fall sick again that is the reason I don’t stop. (Female, PLHIV—
on ART—recently initiated, Malawi)
However, experiences of side effects muddied the continuum
from illness to medication to ‘cure/normality’. In some
instances, the side effects were tolerated as they were deemed
the lesser of two evils in comparison to the illness that was
experienced pre ART. However, others, particularly those who
identiﬁed themselves as well prior to the prescription of ART,
were less able to tolerate such debilitating side effects and
thereby live ‘normal’ lives.
Figure 1 The relation between
antiretroviral therapy and other aspects
of life and treatment. ART,
antiretroviral therapy; HCW, healthcare
workers; PLHIV, people living with HIV.
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The requirement for viral suppression leading to the focus on
adherence and physical pill counts, coupled with the hierarchy
of power loaded on the side of the HCW, was a driver to
adhere/comply. However, these strategies to promote adherence
have dichotomies (as illustrated in ﬁgure 1), namely a lack of
focus on the side effects which led PLHIV to stop taking ART.
The transformational effect of ART enabled many PLHIV to
feel ‘normal’ again; some even reported to be ‘cured’. In this
respect, they were able to resume their daily activities including
returning to formal employment or farming, looking after the
home and children. However, such activities made it harder for
many participants (particularly those who had to travel for
work) to attend their routine clinic visits. Further, there remains
a strong incongruence between the feeling of being ‘cured’ or
‘normal’ and still having to take medication (see ﬁgure 1). We
heard from one PLHIV who was LTFU that he ‘stopped because
[he] was feeling well and was not feeling any pain in [his] body’
(female, PLHIV–LTFU, Zimbabwe). This was reinforced by
many HCWs, one of whom said PLHIV ‘stop taking medicine
because they feel they are healed’ (HCW, Malawi). Feeling
‘normal’ or ‘cured’ led others to not identify as sick, and there-
fore resist or disregard engagement with support groups which
have been well established as important facilitators in retention
in care.16
DISCUSSION
Retention in care is critical for the successful management of
HIV and required in order to reach the United National
Programme on HIV/AIDS ‘90-90-90’ targets.1 2 To our knowl-
edge, this is the ﬁrst multicountry qualitative study to explore
how the bodily and relational experiences of taking ART in dif-
ferent settings impact on retention on ART. Recent quantitative
studies in similar settings found a relationship between the
occurrence of side effects and incomplete adherence.7 Our
in-depth qualitative study elucidates possible reasons for these
increased levels of disengagement. In this paper, we illustrate
that the ‘side effects’ of ART are actually ‘central effects’. Our
ﬁndings suggest that side effects, either when adjusting to treat-
ment or when they return or change, are not treated as serious
complications, with a primary focus driven by a need to achieve
viral suppression.
Our application of practice theory illustrates that relationality
and dichotomies cannot be underestimated, with the presence
of a constant tug between the biomedical requirements for clinic
visits and treatment adherence to obtain viral suppression, on
the one hand, and the immediate needs and desires of PLHIV
to ‘get back to normal’, on the other.16 Our ﬁndings have impli-
cations as we move to the era of ‘test and treat’,17 where diag-
nosed PLHIV may not have experienced feelings of ill-health
nor witnessed the transformational effects of ART. What will be
the motivation for tolerating side effects that undermine ‘nor-
mality’? If the relationality is no longer strong enough, will
people really make an effort to ensure that daily ART become
an integral part of their lives? Our research would suggest that
past illnesses are more likely to lead to greater tolerance of side
effects and therefore earlier treatment prior to sickness or near
death removes the point of comparison and could potentially
limit the motivations required to tolerate them.
In all settings, PLHIV placed value on biomedical indica-
tors such as CD4 counts as a proxy guide for their health
status. A recent study in East Africa found that the lack of
on-site CD4 testing negatively affected engagement in HIV
care.18 Our ﬁndings suggest that the need to measure one’s
‘biological health improvements’ will be affected if the role of
CD4 counts becomes outdated, in light of the imminent ‘test
and treat’ policies. The current attention on the need for
accessible and affordable routine viral load testing to accur-
ately monitor viral suppression19 will be crucial to support
this primarily positive practice to measure one’s health
improvements.
The study demonstrates a continued dichotomy between the
pull of the HCWs to comply with public health policies dictat-
ing their prescription of ART against the individual needs of
each PLHIV. The experiences of PLHIV across the six countries
support the need for differentiated care. Adopting a
‘one-size-ﬁts-all’ practice pertaining to which ARTs, when and
how, could carry negative and unintended consequences as indi-
vidual PLHIV miss opportunities for more comprehensive
assessments of their clinical and social needs.19
There are several strengths and limitations to our study. The
HDSS databases and experienced research teams meant it was
easier to locate, recruit and interview PLHIV who were no
longer in HIV care, although in small numbers. However, as
with many qualitative studies the small sample sizes (particularly
when disaggregated by setting) limit intercountry comparisons.
In each setting, data saturation was achieved, and during ana-
lysis, focus was placed on considering whether salient themes
were more apparent in a given setting over another; however, in
this instance, many of the experiences resonated across all the
counties lending support to the wider generalisability of our
results. Finally, our study was susceptible to social desirability
bias, but this was minimised by ensuring that participants’
accounts would remain conﬁdential and training interviewers to
avoid judgemental reactions.
CONCLUSIONS
Our multicountry qualitative study highlights that retention is
not an outcome of rational knowledge of what one should and
should not do to be retained in care, but is largely an outcome
of bodily knowledge and relational experiences. Such experi-
ences are located in everyday routines and past and present
bodily experiences. Initiatives to improve retention should con-
sider how the bodily and relational experiences of PLHIV
taking ART can be respected and supported by service providers
to subsequently improve retention in care.
Key messages
▸ Many people living with HIV (PLHIV) placed value on
biomedical indicators (eg, CD4 counts or viral loads) as a
proxy guide for their health status. Availability of such
indicators is crucial to positively support PLHIV to be
retained in care.
▸ Side effects of antiretroviral therapy are not treated as
serious complications by health workers who tend to be
driven by a need to achieve viral suppression.
▸ Initiatives to improve retention should consider the potential
consequences of side effects and how these are socially and
relationally conditioned.
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